vimarsana.com
Home
Live Updates
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD : vimarsana.com
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD : vimarsana.com
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health...
Related Keywords
United States ,
Japan ,
Boston ,
Massachusetts ,
Rockville ,
Dana Cormack ,
Jeffreys Heier ,
Chris Brinzey ,
Exchange Commission ,
Drug Administration ,
Nasdaq ,
European Medicines Agency ,
Retina Research At Ophthalmic Consultants Of Boston ,
Clearside Biomedical Inc ,
Corporate Communications ,
Vitreoretinal Service ,
Securities Exchange ,
Chief Executive Officer ,
Retina Research ,
Ophthalmic Consultants ,
Clearside Biomedical ,
Securities Act ,
Securities Exchange Act ,
Financial Condition ,
Novartis Gene ,